跳至主要内容
临床试验/CTRI/2015/10/006266
CTRI/2015/10/006266已完成未知

â??AN INVESTIGATOR - INITIATED, PROSPECTIVE, OBSERVATIONAL STUDY TO OBSERVE THE EFFICACY AND SAFETY OF BRINZOLAMIDE 1% OPHTHALMIC SUSPENSION IN SUBJECTS WITH CHRONIC OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSIONâ??

Dr Rajesh Parekh0 个研究点目标入组 20 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • Written, signed, dated and ethics committee approved informed consent obtained from subjects and/or legally acceptable representative, before performing any screening procedures
  • Male and/or non-pregnant females of age 18 to 65 years [both inclusive] with chronic open angle glaucoma or ocular hypertension in both the eyes on stable ocular hypotensive treatment regimen
  • Newly diagnosed or Subjects who require treatment of both the eyes and is able to discontinue use of all ocular hypotensive medication(s) or switch ocular hypotensive medications and undergo appropriate washout period
  • Adequate wash-out period prior to baseline of any ocular hypotensive medication (see Table No. 1). In order to minimize potential risk to patients due to IOP elevations during the washout period, investigator may choose to substitute a parasympathomimetic or carbonic anhydrase inhibitor in place of a sympathomimetic, alpha-agonist, beta-adrenergic blocking agent, or prostaglandin; however, all patients must have discontinued all ocular hypotensive medication for the minimum washout period provided in Table No. 1
  • Baseline (hour 0) IOP >= 22 mm Hg and <= 34 mm Hg in each eye and any asymmetry of IOP between the eyes which is no greater than 5 mm Hg
  • Baseline best corrected visual acuity equivalent to 20/200 or better in each eye

排除标准

  • Female who are pregnant, breast feeding or planning a pregnancy
  • Female of childbearing potential who do not agree to utilize an adequate form of contraception
  • Current or past history of severe hepatic or renal impairment
  • Current or history of significant ocular disease within two months prior to baseline e.g., corneal edema, uveitis, ocular infection, or ocular trauma in either eye
  • Current corneal abnormalities that would prevent accurate IOP readings with the Goldmann applanation tonometer
  • Functionally significant visual field loss
  • Contraindication to brinzolamide or sulfonamide therapy or known hypersensitivity to any component of brinzolamide or sulfonamide therapy
  • Use of intraocular corticosteroid implant at any time prior to baseline
  • Use of contact lens within one week prior to baseline
  • Use of: a) topical ophthalmic corticosteroid or b) topical corticosteroid within two weeks prior to baseline
  • Use of: a) systemic corticosteroid or b) high-dose salicylate therapy within one month prior to baseline
  • Use of intravitreal or subtenon injection of ophthalmic corticosteroid within six months prior to baseline
  • Performance of any other intraocular surgery (e.g., cataract surgery) within six months prior to baseline
  • Performance of refractive surgery, filtering surgery or laser surgery for IOP reduction within twelve months prior to baseline
  • History of alcohol, chemical or drug abuse or dependence as per DSM IV criteria
  • Current active malignancy or history of malignancy within the past five years
  • Any other clinically significant abnormal medical condition that in the Investigators judgement would put the patient at increased risk of illness or injury would interfere with study participation or would interfere with the evaluation or quality of the data

研究者

发起方
Dr Rajesh Parekh

相似试验

â??PROSPECTIVE, OBSERVATIONAL STUDY TO OBSERVE THE... | 临床试验